News
NICE recommends Rhythm’s Imcivree to help treat obesity and control hunger
Rhythm Pharmaceuticals has announced that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Imcivree – also known as setmelanotide – as an option for treating obesity and controlling hunger caused by pro-opiomelanocortin (POMC) deficiency.